Stem definition | Drug id | CAS RN |
---|---|---|
calcium channel blockers, nifedipine derivatives | 1947 | 39562-70-4 |
Dose | Unit | Route |
---|---|---|
20 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.92 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 16.50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 6.10 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 25 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 8.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1985 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
General physical health deterioration | 76.87 | 33.51 | 55 | 2200 | 115714 | 46568093 |
Antinuclear antibody negative | 71.35 | 33.51 | 12 | 2243 | 228 | 46683579 |
Hypertension | 68.34 | 33.51 | 64 | 2191 | 196292 | 46487515 |
Herpes simplex reactivation | 66.49 | 33.51 | 12 | 2243 | 348 | 46683459 |
Coombs positive haemolytic anaemia | 65.53 | 33.51 | 12 | 2243 | 378 | 46683429 |
Fall | 58.04 | 33.51 | 75 | 2180 | 329022 | 46354785 |
Product prescribing error | 57.37 | 33.51 | 25 | 2230 | 20022 | 46663785 |
Gastritis haemorrhagic | 50.89 | 33.51 | 12 | 2243 | 1314 | 46682493 |
Antiphospholipid syndrome | 47.85 | 33.51 | 12 | 2243 | 1700 | 46682107 |
Complex regional pain syndrome | 45.61 | 33.51 | 12 | 2243 | 2054 | 46681753 |
Hypertensive angiopathy | 44.18 | 33.51 | 7 | 2248 | 90 | 46683717 |
Anxiety disorder | 43.62 | 33.51 | 13 | 2242 | 3498 | 46680309 |
Hypertensive crisis | 39.01 | 33.51 | 17 | 2238 | 13598 | 46670209 |
Premature baby | 37.37 | 33.51 | 18 | 2237 | 18094 | 46665713 |
Lymphopenia | 37.11 | 33.51 | 17 | 2238 | 15276 | 46668531 |
Hyperlipidaemia | 36.98 | 33.51 | 18 | 2237 | 18521 | 46665286 |
Syncope | 36.01 | 33.51 | 34 | 2221 | 104769 | 46579038 |
Erysipelas | 34.93 | 33.51 | 13 | 2242 | 6925 | 46676882 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product prescribing error | 73.18 | 26.80 | 31 | 1981 | 16702 | 29933764 |
Syncope | 60.40 | 26.80 | 48 | 1964 | 84855 | 29865611 |
Dizziness | 59.56 | 26.80 | 69 | 1943 | 194840 | 29755626 |
Osteochondrosis | 38.01 | 26.80 | 9 | 2003 | 719 | 29949747 |
Postrenal failure | 36.94 | 26.80 | 8 | 2004 | 427 | 29950039 |
General physical health deterioration | 36.59 | 26.80 | 39 | 1973 | 99905 | 29850561 |
Source | Code | Description |
---|---|---|
ATC | C08CA08 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
ATC | C09BB06 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002121 | Calcium Channel Blockers |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35620 | vasodilator |
CHEBI has role | CHEBI:35674 | antihypertensive |
CHEBI has role | CHEBI:38215 | calcium channel blockers |
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.37 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | GATING INHIBITOR | IC50 | 8.40 | IUPHAR | IUPHAR | |||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | UNKNOWN | SCIENTIFIC LITERATURE | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 5.52 | DRUG MATRIX | |||||
Voltage-dependent T-type calcium channel subunit alpha-1H | Ion channel | IC50 | 5.06 | WOMBAT-PK | |||||
Transthyretin | Secreted | IC50 | 5.92 | WOMBAT-PK | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 4.44 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5 | CHEMBL | |||||
Voltage-dependent calcium channel gamma-1 subunit | Ion channel | WOMBAT-PK | |||||||
Adenosine receptor A3 | GPCR | Ki | 5.08 | WOMBAT-PK | |||||
Voltage-dependent L-type calcium channel subunit alpha-1F | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR | ||||
Intermediate conductance calcium-activated potassium channel protein 4 | Ion channel | BLOCKER | IC50 | 7.60 | IUPHAR | ||||
Platelet-activating factor receptor | GPCR | Ki | 4.13 | CHEMBL | |||||
Adenosine receptor A2a | GPCR | Ki | 4.64 | CHEMBL | |||||
Adenosine receptor A1 | GPCR | Ki | 5.05 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR | ||||
Voltage-dependent L-type calcium channel subunit alpha-1S | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR |
ID | Source |
---|---|
N0000167238 | NUI |
D00629 | KEGG_DRUG |
C0028127 | UMLSCUI |
CHEBI:7582 | CHEBI |
CHEMBL251230 | ChEMBL_ID |
CHEMBL268609 | ChEMBL_ID |
CHEMBL475534 | ChEMBL_ID |
D009568 | MESH_DESCRIPTOR_UI |
DB01054 | DRUGBANK_ID |
2334 | IUPHAR_LIGAND_ID |
4739 | INN_ID |
9B627AW319 | UNII |
4507 | PUBCHEM_CID |
7441 | RXNORM |
005383 | NDDF |
444757009 | SNOMEDCT_US |
None